Research on the relations between the variation of miRNA-184 before and after treatment of acute myocardial infarction and prognosis.
Several miRNAs have been shown to be released into the circulation and play roles during acute myocardial infarction (AMI). This study aimed at detecting the variation of miRNA-184 before and after treatment of acute myocardial infarction and assessing its prognostic value. 72 AMI patients participated in the study, alongside 10 patients with stable coronary disease and 10 healthy volunteers for comparison. The expression levels of miRNA-184 were measured in AMI patients at 6 h, 12 h, 48 h, 7 d, and 14 d after the onset of symptoms, using blood samples and an RT-PCR method. The levels were compared to single-time levels in the other two groups of individuals. The correlations between the N-terminal pro-brain natriuretic peptide (NT-proBNP) and parameters of the ventricular function (LVEDd and LVEF) and miRNA-184 levels were analyzed taking samples during a one-month follow-up visit. Finally, the correlation between the occurrence rate of major adverse cardiac effects (MACE) and miRNA-184 levels was analyzed evaluating the occurrence of MACE at a one-year follow-up visit. The expression levels of miRNA-184 (6h) were significantly higher than those of the other two groups (p < 0.05). The levels reached a peak 24 h after the onset of symptoms and fell back to normal after 7 to 14 days (at which point the levels were no different than the levels in the other two groups). NT-proBNP and left ventricular end-diastolic diameter (LVEDd) were significantly lower after treatment, whereas the left ventricular ejection fraction (LVEF) increased significantly (p < 0.05). After a relevant Pearson analysis the expression level of miRNA-184 mRNA was positively correlated with ∆NT-proBNP (before and after treatment) (p < 0.05), with ∆LVEDd (before and after treatment) and with ∆LVEF (before and after treatment) (p < 0.05). Finally, 22 cases (36%) of major adverse cardiac events, MACE, were found in AMI patients, and the expression levels of miRNA-184 of the MACE group were significantly higher than those of the non-MACE group at each time point (p < 0.05). miRNA-184 shows a dynamic evolution before and after percutaneous coronary intervention (PCI) treatment of AMI, and it is closely correlated with recent ventricular remodeling indexes and a future occurrence rate of MACE.